Life sciences venture capital major Abingworth is reportedly looking to raise up to $1.5bn in funding to be deployed for clinical development projects partnered with pharma companies in return for future royalties.
Abingworth Tight-Lipped On $1.5bn Clinical Trials Fund Reports
The Carlyle-backed venture capital group is said to be working on a new fund to help finance up to eight late-stage clinical studies through potential partnerships with big pharma for a share of royalties. The move would be in keeping with its recent investment activities.
